- Home
- DMLP vs MYGN Comparison
DMLP vs MYGN Comparison
Compare DMLP & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- MYGN
- Stock Information
- Founded
- DMLP 2003
- MYGN 1991
- Country
- DMLP United States
- MYGN United States
- Employees
- DMLP N/A
- MYGN N/A
- Industry
- DMLP Oil & Gas Production
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DMLP Energy
- MYGN Health Care
- Exchange
- DMLP Nasdaq
- MYGN Nasdaq
- Market Cap
- DMLP 1.5B
- MYGN 1.3B
- IPO Year
- DMLP N/A
- MYGN 1995
- Fundamental
- Price
- DMLP $29.64
- MYGN $9.70
- Analyst Decision
- DMLP
- MYGN Hold
- Analyst Count
- DMLP 0
- MYGN 15
- Target Price
- DMLP N/A
- MYGN $21.37
- AVG Volume (30 Days)
- DMLP 157.9K
- MYGN 1.3M
- Earning Date
- DMLP 05-01-2025
- MYGN 05-06-2025
- Dividend Yield
- DMLP 10.87%
- MYGN N/A
- EPS Growth
- DMLP N/A
- MYGN N/A
- EPS
- DMLP 2.13
- MYGN N/A
- Revenue
- DMLP $154,639,000.00
- MYGN $837,600,000.00
- Revenue This Year
- DMLP N/A
- MYGN $2.97
- Revenue Next Year
- DMLP N/A
- MYGN $8.37
- P/E Ratio
- DMLP $13.99
- MYGN N/A
- Revenue Growth
- DMLP N/A
- MYGN 11.21
- 52 Week Low
- DMLP $28.25
- MYGN $9.36
- 52 Week High
- DMLP $35.74
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- DMLP 38.36
- MYGN 31.73
- Support Level
- DMLP $29.29
- MYGN $9.36
- Resistance Level
- DMLP $30.48
- MYGN $11.44
- Average True Range (ATR)
- DMLP 0.84
- MYGN 0.83
- MACD
- DMLP -0.02
- MYGN -0.16
- Stochastic Oscillator
- DMLP 44.27
- MYGN 6.33
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.